PurPrecision - Right Drug, Right Patient.
TM
Precision neuromedicine is more than a scientific advance, it is a strategic imperative.
​
Neurological disorders represent a profound and escalating global health challenge. In particular, many patients with neurodegenerative diseases have already lost more than 60% of their neurons by the time they are diagnosed, and this loss is irreversible. Despite vast investments in pharmaceutical research, many current therapies remain symptom-focused, often delivering inconsistent results across diverse patient populations. This highlights the limitations of lack of early diagnostic solutions, and the conventional, one-size-fits-all treatment approaches.​
​
Precision neuromedicine transforms care by integrating genetics, biomarkers, multi-omics studies, advanced neuroimaging, and AI-driven diagnostics to create highly personalized interventions. This enables:
-
Earlier and more accurate diagnoses
-
Targeted treatments tailored to each patient’s biology
-
Reduction of trial-and-error prescribing
PurMinds™ has established an exclusive partnership with SpectroChip to deliver next-generation clinical assay capabilities, informed by biomarker and multi-omics studies, in a diagnostic platform with ultra-high sensitivity, portability, universal LFIA compatibility, and cloud connectivity. SpectroChip developed the world’s first photonic chip-based point-of-care testing (POCT) diagnostic platform that integrates the core functionalities of a spectrophotometer, and lateral flow immunoassays (LFIA) into a fingernail-sized photonic chip. This technology is set to transform healthcare by enabling intelligent precision medicine—helping doctors and researchers make faster, smarter, and more personalized decisions. ​
​​
The SpectroChip-PurMinds POCT platform also supports de-centralized point-of-care testing, telehealth and digital health integration with real-time insights, as well as an accessibility and efficiency in 4P medicine ecosystem (personalized, preventative, predictive, and participatory).
For information of SpectroChip Inc., please visit https://www.spectrochips.com
​
PurPrecision™ platform supports smarter, faster, and more cost-efficient clinical trials. By stratifying patients with advanced diagnostics and biomarkers, we:
-
Reduce heterogeneity in trial populations
-
Increase statistical power to detect therapeutic signals
-
Accelerate the development and approval of breakthrough neurological treatments
​
​
By personalizing treatment at its core, we can dramatically improve outcomes, streamline the drug development process, and redefine the future standard of care in neurology.
